S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-13

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

With the Westernization of the diet and insufficient exercise, Taiwan's population of obesity, diabetes, and hyperlipidemia has increased in recent years, and the prevalence of the non-alcoholic fatty liver disease has gradually increased. Although weight loss, dietary adjustments, and certain drug treatments can delay the deterioration of the disease; however, weight loss and dietary adjustment are not easy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors

NCT06244550

Non-alcoholic Fatty Liver Disease Liver Fibrosis Liver Injury

COMPLETED NA

An Open-Label Study to Assess the Hepatic Protection Effect of SNP-612, in Patients With NAFLD

NCT03868566

NASH - Nonalcoholic Steatohepatitis

TERMINATED PHASE2

Study in Healthy Adults Evaluating PF-07202954

NCT04857437

Non-Alcoholic Fatty Liver Disease Liver Fibrosis

COMPLETED PHASE1

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

NCT03776175

Non-Alcoholic Fatty Liver Disease (NAFLD)

COMPLETED PHASE2

A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease

NCT05308160

Fatty Liver

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

With the Westernization of the diet and insufficient exercise, Taiwan's population of obesity, diabetes, and hyperlipidemia has increased in recent years, and the prevalence of the non-alcoholic fatty liver disease has gradually increased. Although weight loss, dietary adjustments, and certain drug treatments can delay the deterioration of the disease; however, weight loss and dietary adjustment are not easy. Moreover, drugs also have side effects, and there is currently no convenient and effective treatment for people who have non-alcoholic fatty liver disease. The purpose of this trial is that investigating and evaluating the effects on fatty liver, liver fiber, and metabolic indexes after subjects using Shen Pu Yang Gan Wan.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Shen Pu Yang Gan Wan

Traditional Chinese Medicine

Group Type EXPERIMENTAL

Shen Pu Yang Gan Wan

Intervention Type DRUG

Shen Pu Yang Gan Wan is Traditional Chinese Medicine; in addition, it has a high dose.

Placebo Comparator

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Shen Pu Yang Gan Wan is Traditional Chinese Medicine; however, it has a very low dose.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Shen Pu Yang Gan Wan

Shen Pu Yang Gan Wan is Traditional Chinese Medicine; in addition, it has a high dose.

Intervention Type DRUG

Placebo

Shen Pu Yang Gan Wan is Traditional Chinese Medicine; however, it has a very low dose.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with fatty liver diagnosed by abdominal ultrasound or hepatic fibrometer within half a year's data
* Subjects with the non-alcoholic fatty liver disease
* The severity of fatty liver should be at least 3 points by taking an abdominal ultrasound

Exclusion Criteria

* Female patients are pregnant or breastfeeding.
* Patients with viral hepatitis.
* Long-term drinkers.
* Those who use slimming products and vitamin E.

Minimum Eligible Age

35 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No